



REWARDSTREAM TO ACQUIRE ISREALI CANNABIS LICENSEE

Vancouver, British Columbia, May 2, 2019 – RewardStream Solutions Inc. (TSXV: REW and Frankfurt: JL4L, WKN Number A2APX1) (the “**Company**”) is pleased to announce it has entered into a letter of intent (the “**Letter**”), dated effective April 30, 2019, pursuant to which it proposes to acquire (the “**Transaction**”) all of the outstanding share capital of EuroMed Therapeutics Ltd. (“**EuroMed**”). EuroMed is an arms’-length company, established under the laws of the Province of British Columbia, involved in the cultivation and exporting of medical grade cannabis produced in greenhouse facilities located in Israel. EuroMed aims to be a leading low-cost high-quality medical grade cannabis producer in Israel with a focus on both the domestic Israeli market and the emerging European cannabis market.

EuroMed, through its wholly-owned Israeli subsidiary, Eurocann Agritech Ltd., owns a 74% equity stake in a 269,098 square foot (25 dunam) cannabis designated cultivation property located 45 minutes outside of Jerusalem, Israel. EuroMed intends to build a 22,000 square feet greenhouse facility on the property to cultivate medical grade cannabis for the purposes of servicing the domestic medical cannabis market and exports into Europe. EuroMed will be working with leading greenhouse engineering and construction firm Eisenberg Agri Company (Israel) Limited (EACi) to design and build a state of the art modular greenhouse facility with expected completion by March 2020.

In accordance with the terms of the Transaction, the Company proposes to consolidate its outstanding share capital (the “**Share Consolidation**”) on a two-for-one basis, and issue 40,000,000 post-Share Consolidation common shares (the “**Consideration Shares**”) to the shareholders of EuroMed in exchange for all of the outstanding share capital of EuroMed. Following completion of the Share Consolidation, and the issuance of the Consideration Shares, the Company is expected to have approximately 48,741,562 common shares outstanding. At this time, the issuance of the Consideration Shares to the shareholders of EuroMed is not expected to result in the creation of any new insiders or control persons of the Company.

Prior to closing of the Transaction, the Company intends to apply to list its common shares on the Canadian Securities Exchange, and voluntarily delist its shares from the TSX Venture Exchange. On closing of the Transaction, it is anticipated that the Company will change its name to “EuroMed Therapeutics Ltd.”, and will reconstitute its board and management to consist of members mutually agreeable to the Company and EuroMed.

In connection with completion of the Transaction, the Company intends to undertake a non-brokered private placement (the “**Financing**”) of subscription receipts to raise not less than \$2,500,000. The Company will provide additional information regarding the terms of the Financing as soon as it becomes available.

In connection with the Transaction, the Company anticipates issuing 4,000,000 post-Share Consolidation common shares to an arms’-length third party who assisted in introducing the Transaction to the Company. All securities issued in connection with the Transaction, and the Financing, will be subject to a four-month-and-one-day statutory hold period.

Completion of the Transaction remains subject to a number of conditions, including the completion of satisfactory due diligence, the negotiation and finalization of definitive



documentation, receipt of any required regulatory and third-party consents, approval of minority shareholders of the Company to the delisting of the Company's common shares from the TSX Venture Exchange, completion of the Share Consolidation, completion of the Financing, the Canadian Securities Exchange having conditionally accepted the listing of the Company's common shares, the TSX Venture Exchange having consented to the voluntarily delisting of the Company's common shares, and the satisfaction of other customary closing conditions.

The Transaction cannot close until the required approvals are obtained, and the Company's common shares have been delisted from the TSX Venture Exchange. There can be no assurance that the Transaction will be completed as proposed or at all, or that the Company's common shares will be listed and posted for trading on any stock exchange. Trading in the Company's common shares is currently suspended and it is anticipated that trading will remain suspended until completion of the Transaction.

Further information regarding the Transaction, including the terms of the Financing, a detailed use of proceeds for the Financing, financial information of EuroMed, and details regarding the proposed board and management of the Company following completion of the Transaction, will be made available in due course. Readers are encouraged to review the listing statement which will be prepared by the Company in connection with the listing of the Company on the Canadian Securities Exchange, and which will be made available under the Company's profile on SEDAR (www.sedar.com).

For more information contact:

Patrick Morris, Chief Executive Officer
pm@primaryenergymetals.com or 604-283-1722

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Neither the TSX Venture Exchange, nor the Canadian Securities Exchange, has in any way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this press release.

Completion of the Transaction is subject to a number of conditions, including but not limited to, the consent of the TSX Venture Exchange to the delisting of the Company, the Canadian Securities Exchange having conditionally accepted the listing of the Company, and disinterested shareholder approval. The Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the listing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.

This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the terms and conditions of the proposed Transaction; and the proposed listing of the



Company on the Canadian Securities Exchange. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties, uncertain capital markets; and delay or failure to receive board, shareholder or regulatory approvals. There can be no assurance that the Transaction will proceed on the terms contemplated above or at all and that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.